Medicare and Medicaid

Medicare Coverage for Microvolt T-Wave Alternans Testing; Patented Analytic Spectral Method Required

Published in Medical Patent Law Weekly, February 27th, 2008

Cambridge Heart, Inc. (OTCBB: CAMH), announced the publication of a proposed decision memorandum regarding Medicare coverage of Microvolt T-wave Alternans (MTWA) diagnostic testing. The Centers for Medicare & Medicaid Services (CMS) maintained coverage of MTWA using the spectral analysis method and found insufficient evidence for coverage of MTWA using any other method.

The proposed decision memorandum is the result of CMS's six-month evaluation of the relevant clinical evidence available to the agency and consideration of public comments submitted on the request to expand coverage to include the Modified Moving Average (MMA) methodology. The memorandum proposes to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly

Source: Medical Patent Law Weekly (2008-02-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry